Far-Infrared Therapy: A Novel Treatment to Improve Access Blood Flow and Unassisted Patency of Arteriovenous Fistula in Hemodialysis Patients

August 1, 2007

Abstract

Vascular access malfunction, usually presenting with an inadequate access flow (Qa), is the leading cause of morbidity and hospitalization in hemodialysis (HD) patients. Many methods of thermal therapy have been tried for improving Qa but with limited effects. This randomized trial was designed to evaluate the effect of far-infrared (FIR) therapy on access flow and patency of the native arteriovenous fistula (AVF). A total of 145 HD patients were enrolled with 73 in the control group and 72 in the FIR group. A WS TY101 FIR emitter was used for 40 min, and hemodynamic parameters were measured by the Transonic HD02 monitor during HD. The Qa1 /Qa2 and Qa3 /Qa4 were defined as the Qa measured at the beginning/at 40 min later in the HD session before the initiation and at the end of the study, respectively. The incremental change of Qa in the single HD session with FIR therapy was significantly higher than that without FIR therapy (13.2 114.7 versus 33.4 132.3 ml/min; P 0.021). In comparison with control subjects, patients who received FIR therapy for 1 yr had (1) a lower incidence (12.5 versus 30.1%; P < 0.01) and relative incidence (one episode per 67.7 versus one episode per 26.7 patient-months; P 0.03) of AVF malfunction; (2) higher values of the following parameters, including (Qa4 Qa3 ) (36.2 82.4 versus 12.7 153.6 ml/min; P 0.027), (Qa3 Qa1 ) (36.3 166.2 versus 51.7 283.1 ml/min; P 0.035), (Qa4 Qa2 ) (99.2 144.4 versus 47.5 244.5 ml/min; P < 0.001), and (Qa4 Qa2 ) (Qa3 Qa1 ) (62.9 111.6 versus 4.1 184.5 ml/min; P 0.032); and (3) a better unassisted patency of AVF (85.9 versus 67.6%; P < 0.01). In conclusion, FIR therapy, a noninvasive and convenient therapeutic modality, can improve Qa and survival of the AVF in HD patients through both its thermal and its nonthermal effects.

 -J Am Soc Nephrol 18: 985–992, 2007. doi: 10.1681/ASN.2006050534

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
FIRAPY collaborates with Taipei Veterans General Hospital in research on non-invasive therapies for

FIRAPY Supports Clinical Research Advancing Non-Invasive Therapies for Peritoneal Dialysis

July 2, 2025
FIRAPY and Taipei Veterans General Hospital co-published a study in JFMA showing improved cardiovascular and infection outcomes in peritoneal dialysis patients using far-infrared therapy.
FIR improves cardiovascular and infectious outcomes inPD patients

Far-infrared therapy improves cardiovascular and infectious outcomes in peritoneal dialysis patients

July 2, 2025
Abstract

FIRAPY to Exhibit at 70th JSDT Annual Meeting in Yokohama

June 17, 2025
We are pleased to announce that FIRAPY will be exhibiting at the 70th Annual Meeting of the Japanese Society for Dialysis Therapy (JSDT) , to be held in OSAKA , Japan , from June 27-29, 2025 . 📍 Booth No.: ⑩-96 📅 June 27–29, 2025 📌 Osaka International Convention Center 🔗 Event Website (Japanese) FIRAPY is now adopted by over 200 dialysis facilities across Japan , where it has been used in daily clinical practice to support fistula function maintenance and foot care . With this extensive local experience, FIRAPY has become an important part of non-invasive treatment for Japanese HD patients. We look forward to sharing our latest clinical insights and field experiences at JSDT 2025. If you are attending, we warmly welcome you to stop by Booth ⑩-96 and learn more about how FIRAPY is making a difference in dialysis care. See you in Osaka!
More Posts